Two drug makers withdraw bladder cancer indications

Tom Smith

For the second time in less than a month, a drug maker has pulled an indication for a medicine after a stick to-up scientific trial failed to meet its major objective. And the moves come as aspect of a U.S. regulatory critique of so-identified as accelerated approvals, a controversial approach that […]

For the second time in less than a month, a drug maker has pulled an indication for a medicine after a stick to-up scientific trial failed to meet its major objective. And the moves come as aspect of a U.S. regulatory critique of so-identified as accelerated approvals, a controversial approach that has been utilised to hasten availability of treatments for critical conditions.

The newest reversal issues Tecentriq, a Roche (RHHBY) drug that was granted accelerated approval in 2016 to handle bladder cancer, but a demo to affirm the rewards subsequently showed it failed to boost in general survival. Very last month, AstraZeneca (AZN) withdrew a bladder cancer indication for Imfinzi right after a observe-up trial also showed the drug unsuccessful to increase general survival.

Unlock this report by subscribing to STAT+ and get pleasure from your initially 30 days no cost!

GET Started

Next Post

Teva launches Indoco Solutions-designed generic drug in US, Health News, ET HealthWorld

Indoco Remedies on Tuesday stated Teva Pharmaceuticals has introduced Brinzolamide ophthalmic suspension used in the cure of elevated intraocular stress in patients with ocular hypertension or open-angle glaucoma in the United States. The product or service, which is a generic edition of Azopt ophthalmic suspension, is produced and manufactured by […]

Subscribe US Now